About CytomX Therapeutics, Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Market Cap
$0.05B
Employees
121
Listed Since
October 8, 2015
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cytomx.comPhone
650.515.3185
Headquarters
151 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
CIK
0001501989